GMAB

Genmab AS (GMAB)

Genmab AS

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:GMAB

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/01	23 : 00	Business Wire	Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	NASDAQ:GMAB	Genmab AS
2024/05/29	00 : 29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/05/24	06 : 00	Business Wire	Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting	NASDAQ:GMAB	Genmab AS
2024/05/22	00 : 38	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/05/22	00 : 18	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/05/22	00 : 10	Business Wire	Genmab Completes Acquisition of ProfoundBio	NASDAQ:GMAB	Genmab AS
2024/05/14	23 : 05	Business Wire	Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress	NASDAQ:GMAB	Genmab AS
2024/05/14	00 : 29	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/04/30	07 : 40	Business Wire	TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/04/30	07 : 40	Business Wire	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/04/03	14 : 35	Business Wire	Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio	NASDAQ:GMAB	Genmab AS
2024/03/12	02 : 43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/03/05	03 : 50	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/03/05	03 : 26	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/03/02	07 : 04	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:GMAB	Genmab AS
2024/03/01	01 : 47	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/29	01 : 06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/28	06 : 55	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/27	21 : 45	Business Wire	U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma	NASDAQ:GMAB	Genmab AS
2024/02/27	02 : 19	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/27	00 : 40	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/23	06 : 28	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:GMAB	Genmab AS
2024/02/21	01 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/15	05 : 42	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/15	03 : 49	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:GMAB	Genmab AS
2024/02/15	02 : 30	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/02/02	20 : 45	Business Wire	Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer	NASDAQ:GMAB	Genmab AS
2024/02/01	01 : 17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/01/23	23 : 04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:GMAB	Genmab AS
2024/01/09	21 : 45	Dow Jones News	Pfizer, Genmab Get Speedy FDA Review of Tivdak Full Approval	NASDAQ:GMAB	Genmab AS